Sign up USA
Proactive Investors - Run By Investors For Investors

Summit Therapeutics PLC's ridinilazole results continue to impress

Shares in Summit Therapeutics went higher as it revealed its new antibiotic for hospital superbug C.Diff could treat the disease and help stop it reoccurring.
Summit Therapeutics PLC's ridinilazole results continue to impress
Clostridium difficile, or C-diff, is a big threat in hospitals and care homes...

Shares in Summit Therapeutics PLC (NASDAQ: SMMT, LON: SUMM) went higher as it revealed its new antibiotic for hospital superbug C.Diff could treat the disease and help stop it reoccurring.

The further positive data comes from the CoDIFy Phase 2 clinical trial  and showed that ridinilazole can preserve the micobiome in the gut as it treats the condition, while the standard of care medicine - vancomycin - causes "substantial and long-lasting damage" on the microbiome, or the eco-system of the gut.

Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.

Glyn Edwards, chief executive of Summit, told investors: "These new results from the Phase 2 trial show ridinilazole preserves the patients' microbiome while simultaneously working to eradicate the C. difficile bacteria.

"The clinical data strongly suggest that ridinilazole treatment may be better able to protect against recurrent disease than the current standard of care.

"We believe this approach offers a clear advantage over conventional broad spectrum antibiotics currently used to treat CDI that cause substantial damage to the gut microbiome or approaches that aim to artificially re-establish a damaged gut microbiome following antibiotic treatment."

Summit reckons ridinilazole could become a single therapeutic approach capable of both treating the initial infection and reducing the high rates of recurrent disease.

Today's findings come after recently reported results from the Phase 2 CoDIFy trial that showed ridinilazole to be statistically superior to vancomycin in sustained clinical response.

C. diff is a serious threat in hospitals and care homes and there are between 450,000 and 700,000 cases in the US annually.

It is caused by an infection of the colon by the bacterium C. difficile, which produces toxins that causes inflammation, severe diarrhoea and in the most serious cases can be fatal.

Biopharma Summit, listed in London and New York, as well as C-diff, is focused on developing a treament for Duchenne muscular dystrophy.

Shares advanced in London 4.55% to 103.5p.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Newswire
October 04 2017

Related Articles

scientist in a lab
September 27 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use